Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Utah Medical Products (UTMD) over the last 3 years, with Q3 2021 value amounting to $11000.0.

  • Utah Medical Products' Amortization of Deferred Charges rose 1000.0% to $11000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $42000.0, marking a year-over-year increase of 1052.63%. This contributed to the annual value of $39000.0 for FY2020, which is 263.16% up from last year.
  • According to the latest figures from Q3 2021, Utah Medical Products' Amortization of Deferred Charges is $11000.0, which was up 1000.0% from $11000.0 recorded in Q2 2021.
  • Over the past 5 years, Utah Medical Products' Amortization of Deferred Charges peaked at $11000.0 during Q2 2021, and registered a low of $9000.0 during Q2 2019.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $10000.0 (2019), whereas its average is $9909.1.
  • Data for Utah Medical Products' Amortization of Deferred Charges shows a peak YoY increase of 1111.11% (in 2020) and a maximum YoY decrease of 1000.0% (in 2020) over the last 5 years.
  • Utah Medical Products' Amortization of Deferred Charges (Quarter) stood at $9000.0 in 2019, then increased by 11.11% to $10000.0 in 2020, then increased by 10.0% to $11000.0 in 2021.
  • Its last three reported values are $11000.0 in Q3 2021, $11000.0 for Q2 2021, and $10000.0 during Q1 2021.